Title
Category
Credits
Event date
Cost
Inside Myasthenia Gravis: Where Providers and Patients Diverge on Defining Treatment Success
$0.00
Program DescriptionThe understanding and prognosis of patients with myasthenia gravis (MG) have made dramatic leaps since the advent of serological evaluation and immunotherapy. In fact, clinicians have become so confident in the ability to diagnose and manage MG that prominent medical organizations commonly boast the ability of these patients to lead “normal lives.” However, studies find that clinician and patient perceptions are often not the same.
Over-Impacted, Under-Represented: Addressing Health Disparities in Multiple Sclerosis
$0.00
Program DescriptionThe prevalence of multiple sclerosis (MS) in racial and ethnic minority groups appears to be growing and its prognosis among these groups is often worse. With its historical management strategies formulated almost exclusively around patients of Caucasian descent, MS has a pressing need for improved approaches in patients of minority backgrounds. However, minimal guidance is publicly available on how to best meet the needs of diverse patient populations.
Decoding CIDP Strategies to Overcome Common Diagnostic and Therapeutic Pitfalls
$0.00
Due to the unique educational design of this course, the content must be viewed and completed on the myCME platform.Program DescriptionChronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder whose treatment landscape has recently expanded with the introduction of novel therapies with unique mechanisms of action and routes of administration. Despite these advances, CIDP is prone to misdiagnosis.
Out of the Dark, Into the Light: Illuminating Modern Strategies for the Detection and Treatment of Bipolar Depression (Credit Expired)
$0.00
OverviewUp to 80% of patients with bipolar disorder (BD) initially present with depression. However, without experience of or insight into their mania, these patients are easily misdiagnosed with major depressive disorder (MDD) or other psychiatric conditions. Once an accurate diagnosis is obtained, ensuring appropriate treatment of BD depression is essential, but a variety of misconceptions and outdated strategies significantly complicate this process.
Across the Spectrum: Transforming the Detection and Management of Disease State Transitions Across the Spectrum of Multiple Sclerosis (Credit Expired)
$0.00
Program DescriptionMultiple sclerosis (MS) is a disease of transitions from subclinical changes to isolated events to definite MS. These clinical developments are often accompanied by changes in disease states ranging from active to inactive. But with increasing recognition that progressive pathologies may begin early in MS, the lines between disease states are beginning to blur.
Broadening the Treatment Horizon: Examining the Expanding Roles of New Therapies in Epilepsy Management (Credit Expired)
$0.00
Program DescriptionRecent advances in the understanding of the genetics of epilepsy have led to new insights that stand to significantly improve treatment for individual patient presentations and needs. With several anti-seizure medications (ASMs) now approved (e.g., cannabidiol, fenfluramine, ganaxolone) for syndromes with expanding indications, genetic testing may impact treatment decisions for a large population of patients.
Lost in Transition: Pearls From An Interactive Workshop to Improve the Journey to Adulthood in Spinal Muscular Atrophy
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
$0.00
Program DescriptionHistorically, patients with the most severe forms of spinal muscular atrophy (SMA) were largely unable to survive into adulthood, and those that did often were treated with a palliative approach. However, with the arrival of therapies that can dramatically shift the path of the disease, more and more patients are entering life-long adult care. Unfortunately, as this transition is a new consideration, many clinicians are still learning how to coordinate and manage it appropriately. 
The Path to Least Resistance: The Emerging Role of Noncovalent BTK Inhibitors in CLL/SLL Across Clinical Practice Settings
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
$0.00
Program DescriptionThe advent of covalent Bruton’s tyrosine kinase inhibitors (cBTKi) (e.g., ibrutinib) in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has significantly enhanced long-term outcomes and quality-of-life for patients as the treatment landscape continues to shift away from traditional chemoimmunotherapy approaches. However, many patients eventually develop treatment resistance, driving disease progression and further limiting therapeutic options.
The ARIA Toolkit: An Interdisciplinary Curriculum to Optimize Team-Based Management of Amyloid-Related Imaging Abnormalities in Alzheimer’s Disease
$0.00
Due to the unique educational design of this course, the content must be viewed and completed on the ReachMD platform.Program DescriptionThe introduction of disease modifying amyloid targeting therapies for Alzheimer’s disease is creating a paradigm shift in the treatment of patients with this condition. But the potential for ARIA prompts several unique considerations over the course of therapy.
Alzheimer’s Disease Diagnosis Time Outs: A Deep Dive into Challenging Clinical Scenarios for Early Alzheimer's Diagnosis and Treatment
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionThe management of AD is at the beginning of a seismic paradigm shift. Historically, clinical strategy has been tailored to a therapeutic armamentarium that was nonspecific and directed solely at symptom management. This mindset coincides with a variety of outdated and potentially harmful assumptions such as the idea that early diagnosis provides limited clinical value. Now that anti-Aβ antibodies are making their way into the clinic, the entire spectrum of AD care, from diagnosis through therapy, must be re-engineered.

Pages